Description

Belumosudil (REZUROCK) is an oral serine/threonine kinase inhibitor targeting Rho-associated coiled-coil kinase 2 (ROCK2) and, to a lesser extent, ROCK1. It suppresses pro-inflammatory Th17 cytokine activity (IL?17A, IL?21), and promotes regulatory T?cell balance. Approved for chronic graft-versus-host disease, REZUROCK offers immunomodulatory and anti-fibrotic properties. In research, these tablets are used to simulate immune-fibrotic disease pathways, study inflammation resolution, and assess ROCK2-targeted pharmacodynamics. Each box contains thirty 0.2?g tablets. For laboratory research use only.

Product Specifications

Mechanism of Action & Research Applications

Belumosudil selectively inhibits ROCK2, reducing Th17?mediated cytokines and enhancing regulatory T-cell activity. It addresses both inflammation and fibrotic signaling. In research, REZUROCK is used for:

• Modeling chronic graft?versus?host disease immune-fibrotic mechanisms

• Studying IL?17A/IL?21 pathology in autoimmune and inflammatory disease models

• Evaluating ROCK2 inhibition in pulmonary fibrosis models

• Investigating cytokine modulation and STAT signaling pathways
  For laboratory research use only.

Side Effects (For Reference Only in Research Models)

Observations from clinical and preclinical data include infections, fatigue, gastrointestinal discomfort, cough, edema, hypertension, headache, bleeding, and lymphocyte/platelet changes. Embryo-fetal toxicity observed in animal studies; contraceptive precautions recommended. These serve as safety references for experimental dosing protocols.

Disclaimer

REZUROCK Belumosudil Mesylate Tablets are solely for laboratory research use. Not intended for human or veterinary therapeutic or diagnostic use.